|
Shares of Germany's biggest lender rose 1.86 percent after major
clients and rivals extended support to the bank, which is
negotiating with U.S. authorities over a multi-billion dollar
penalty.
Deutsche Bank's U.S.-listed stock <DB.N> rose 2 percent in
premarket trading.
"It looks like we have one of those choppy, directionless days
unless we get something from Deutsche Bank," said Matthew
Tuttle, chief investment officer at Tuttle Tactical Management
in Riverside, Connecticut.
The British pound fell to a 31-year low as concerns over the
country's separation from the European Union resurfaced.
London's FTSE <.FTSE> was up nearly 2 percent, hovering near its
record high, as investors cheered the idea of a weaker pound
boosting exports.
Richmond Federal Reserve President Jeffrey Lacker said there was
a strong case for raising rates. His Cleveland counterpart,
Loretta Mester, who unlike Lacker is a voting member of the Fed,
said on Monday that the central bank should not delay raising
rates.
The September jobs report on Friday will give a glimpse into the
health of the U.S. labor market and play a big role in the Fed's
decision on interest rates.
Traders have priced in a mere 10 percent chance of a hike at the
Fed's November meeting, which comes days before the Nov. 8 U.S.
presidential election. The odds of a December hike stand at 62
percent, according to the CME Group's FedWatch tool.
The dollar index <.DXY> surged to a near two-week high, adding
0.6 percent as improving economic data boosted the chances of a
rate hike in the coming months.
Dow e-minis <1YMc1> were up 3 points, or 0.02 percent at 8:14
a.m. ET, with 12,911 contracts changing hands.
S&P 500 e-minis <ESc1> were up 0.75 points, or 0.03 percent,
with 132,719 contracts traded.
Nasdaq 100 e-minis <NQc1> were up 5.75 points, or 0.12 percent,
on volume of 18,731 contracts.
Darden <DRI.N> shares rose 4.6 percent to $64.15 in premarket
trading after the restaurant chain operator reported a rise in
first-quarter sales.
Netflix rose 1.72 percent to $104.20 amid speculation that the
company could be a takeover target.
Sarepta Therapeutics rose 1.62 percent after entering an
agreement with Summit Therapeutics to develop drugs to treat
Duchenne muscular dystrophy. Summit's U.S.-listed stock was up
83.8 percent.
Pandora rose 4.2 percent after Goldman Sachs added the stock to
its "conviction list" and raised its price target.
(Reporting by Yashaswini Swamynathan in Bengaluru; Editing by
Anil D'Silva)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|
